Condition
Transthyretin Amyloid Cardiopathy
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Withdrawn2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04843020Phase 2WithdrawnPrimary
ION-682884 in Patients With TTR Amyloid Cardiomyopathy
NCT06651073Active Not RecruitingPrimary
ATTR-CM: A Multi-country, Non-interventional Disease Registry
NCT05633563Phase 4CompletedPrimary
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
NCT02713880Withdrawn
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)
Showing all 4 trials